PedAM

Pediatric Disease Annotations & Medicines


	obsessive-compulsive disorder

Disease ID	277
Disease	obsessive-compulsive disorder
Definition	An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension.
Synonym	#NAME? [x]obsessive-compulsive disorder, unspecified [x]obsessive-compulsive disorder, unspecified (disorder) anancastic neurosis anankastic neurosis anankastic personalities disorder, obsessive-compulsive disorders, obsessive-compulsive neuroses, obsessive-compulsive neurosis, obsessive compulsive neurosis, obsessive-compulsive obsessive compulsive dis obsessive compulsive disorder obsessive compulsive disorder (disorder) obsessive compulsive disorder (ocd) obsessive compulsive disorder, nos obsessive compulsive neurosis obsessive-compulsive disorder (disorder) obsessive-compulsive disorder [disease/finding] obsessive-compulsive disorder nos obsessive-compulsive disorder nos (disorder) obsessive-compulsive disorders obsessive-compulsive neuroses obsessive-compulsive neurosis obsessive-compulsive psychoneurosis or reaction obsessive-compulsive reaction ocd - obsessive-compulsive disorder personalities, anankastic personality, anankastic reaction obsessive-compulsive
OMIM	OMIM:164230
DOID	DOID:10933
ICD10	ICD10CM:F42
UMLS	C0028768
MeSH	D009771
SNOMED-CT	SNOMEDCT_US_2016_09_01:191736004
Comorbidity	UMLS \| Disease \| Sentences' Count(Total Sentences:35) C0003467 \| anxiety \| 10 C0011570 \| depression \| 8 C0003469 \| anxiety disorder \| 4 C0036341 \| schizophrenia \| 4 C0041696 \| major depression \| 4 C0040188 \| tic disorders \| 3 C0003469 \| anxiety disorders \| 3 C0026769 \| multiple sclerosis \| 2 C0001818 \| agoraphobia \| 2 C0033975 \| psychotic disorder \| 2 C0005586 \| bipolar disorder \| 2 C0005586 \| bipolar affective disorder \| 2 C0031212 \| personality disorders \| 2 C0013473 \| eating disorders \| 2 C0030567 \| parkinson's disease \| 2 C0013473 \| eating disorder \| 2 C0679466 \| cognitive deficits \| 2 C0004352 \| autism \| 1 C0030319 \| panic disorder \| 1 C0011860 \| diabetes mellitus type 2 \| 1 C0031572 \| social phobia \| 1 C0041341 \| tuberous sclerosis \| 1 C0033953 \| sexual dysfunction \| 1 C0034735 \| raynaud's phenomenon \| 1 C0036341 \| schizophrenic disorders \| 1 C0149931 \| migraines \| 1 C0033860 \| psoriasis \| 1 C0025235 \| melkersson-rosenthal syndrome \| 1 C0002020 \| alexithymia \| 1 C0033975 \| psychotic disorders \| 1 C0041696 \| major depressive disorder \| 1 C0012746 \| dissociative disorder \| 1 C0162671 \| melas syndrome \| 1 C0033975 \| psychosis \| 1 C0027404 \| narcolepsy \| 1
Curated Gene	Entrez_id \| Symbol \| Resource(Total Genes:7) SLC6A4 \| 6532 \| CTD_human HTR2A \| 3356 \| CTD_human BDNF \| 627 \| CTD_human CCKBR \| 887 \| CTD_human HTR1D \| 3352 \| CTD_human SLITRK5 \| 26050 \| CTD_human HOXB8 \| 3218 \| CTD_human
Inferring Gene	Entrez_id \| Symbol \| Resource(Total Genes:21) 627 \| BDNF \| infer 1312 \| COMT \| infer 1814 \| DRD3 \| infer 1815 \| DRD4 \| infer 2898 \| GRIK2 \| infer 2899 \| GRIK3 \| infer 2904 \| GRIN2B \| infer 3351 \| HTR1B \| infer 3352 \| HTR1D \| infer 3356 \| HTR2A \| infer 3358 \| HTR2C \| infer 3359 \| HTR3A \| infer 4128 \| MAOA \| infer 4916 \| NTRK3 \| infer 6505 \| SLC1A1 \| infer 6531 \| SLC6A3 \| infer 6532 \| SLC6A4 \| infer 7124 \| TNF \| infer 345651 \| ACTBL2 \| infer 167691 \| LCA5 \| infer 4915 \| NTRK2 \| infer
Text Mined Gene	Entrez_id \| Symbol \| Score \| Resource(Total Genes:231) 618 \| BCYRN1 \| DISEASES 27184 \| DISC2 \| DISEASES 51087 \| YBX2 \| DISEASES 1015 \| CDH17 \| DISEASES 1815 \| DRD4 \| DISEASES 5607 \| MAP2K5 \| DISEASES 4710 \| NDUFB4 \| DISEASES 50 \| ACO2 \| DISEASES 5173 \| PDYN \| DISEASES 5020 \| OXT \| DISEASES 6530 \| SLC6A2 \| DISEASES 4849 \| CNOT3 \| DISEASES 11129 \| CLASRP \| DISEASES 4818 \| NKG7 \| DISEASES 1075 \| CTSC \| DISEASES 55907 \| CMAS \| DISEASES 81491 \| GPR63 \| DISEASES 5754 \| PTK7 \| DISEASES 1007 \| CDH9 \| DISEASES 9168 \| TMSB10 \| DISEASES 3485 \| IGFBP2 \| DISEASES 58512 \| DLGAP3 \| DISEASES 3218 \| HOXB8 \| DISEASES 5217 \| PFN2 \| DISEASES 22865 \| SLITRK3 \| DISEASES 7425 \| VGF \| DISEASES 7166 \| TPH1 \| DISEASES 4738 \| NEDD8 \| DISEASES 10439 \| OLFM1 \| DISEASES 51540 \| SCLY \| DISEASES 6616 \| SNAP25 \| DISEASES 3357 \| HTR2B \| DISEASES 9177 \| HTR3B \| DISEASES 1559 \| CYP2C9 \| DISEASES 9360 \| PPIG \| DISEASES 6095 \| RORA \| DISEASES 6532 \| SLC6A4 \| DISEASES 10021 \| HCN4 \| DISEASES 4591 \| TRIM37 \| DISEASES 6505 \| SLC1A1 \| DISEASES 25939 \| SAMHD1 \| DISEASES 2901 \| GRIK5 \| DISEASES 6492 \| SIM1 \| DISEASES 57084 \| SLC17A6 \| DISEASES 2033 \| EP300 \| DISEASES 7379 \| UPK2 \| DISEASES 8527 \| DGKD \| DISEASES 54431 \| DNAJC10 \| DISEASES 2892 \| GRIA3 \| DISEASES 57575 \| PCDH10 \| DISEASES 5443 \| POMC \| DISEASES 11343 \| MGLL \| DISEASES 6507 \| SLC1A3 \| DISEASES 56922 \| MCCC1 \| DISEASES 55749 \| CCAR1 \| DISEASES 1000 \| CDH2 \| DISEASES 6531 \| SLC6A3 \| DISEASES 6581 \| SLC22A3 \| DISEASES 3358 \| HTR2C \| DISEASES 139818 \| DOCK11 \| DISEASES 6570 \| SLC18A1 \| DISEASES 1392 \| CRH \| DISEASES 6506 \| SLC1A2 \| DISEASES 2904 \| GRIN2B \| DISEASES 51594 \| NBAS \| DISEASES 2893 \| GRIA4 \| DISEASES 2911 \| GRM1 \| DISEASES 3192 \| HNRNPU \| DISEASES 114791 \| TUBGCP5 \| DISEASES 84976 \| DISP1 \| DISEASES 23522 \| KAT6B \| DISEASES 6750 \| SST \| DISEASES 3361 \| HTR5A \| DISEASES 3362 \| HTR6 \| DISEASES 1742 \| DLG4 \| DISEASES 431707 \| LHX8 \| DISEASES 4009 \| LMX1A \| DISEASES 85477 \| SCIN \| DISEASES 63974 \| NEUROD6 \| DISEASES 115825 \| WDFY2 \| DISEASES 6571 \| SLC18A2 \| DISEASES 79158 \| GNPTAB \| DISEASES 89832 \| CHRFAM7A \| DISEASES 6632 \| SNRPD1 \| DISEASES 4054 \| LTBP3 \| DISEASES 5617 \| PRL \| DISEASES 3603 \| IL16 \| DISEASES 51181 \| DCXR \| DISEASES 2915 \| GRM5 \| DISEASES 2353 \| FOS \| DISEASES 255239 \| ANKK1 \| DISEASES 140886 \| PABPC5 \| DISEASES 3054 \| HCFC1 \| DISEASES 3352 \| HTR1D \| DISEASES 3350 \| HTR1A \| DISEASES 9229 \| DLGAP1 \| DISEASES 170572 \| HTR3C \| DISEASES 3355 \| HTR1F \| DISEASES 5021 \| OXTR \| DISEASES 23191 \| CYFIP1 \| DISEASES 8227 \| AKAP17A \| DISEASES 124152 \| IQCK \| DISEASES 1272 \| CNTN1 \| DISEASES 1812 \| DRD1 \| DISEASES 284359 \| IZUMO1 \| DISEASES 1946 \| EFNA5 \| DISEASES 706 \| TSPO \| DISEASES 121278 \| TPH2 \| DISEASES 83943 \| IMMP2L \| DISEASES 277 \| AMY1B \| DISEASES 10215 \| OLIG2 \| DISEASES 5580 \| PRKCD \| DISEASES 2903 \| GRIN2A \| DISEASES 23762 \| OSBP2 \| DISEASES 10810 \| WASF3 \| DISEASES 285242 \| HTR3E \| DISEASES 885 \| CCK \| DISEASES 64359 \| NXN \| DISEASES 123606 \| NIPA1 \| DISEASES 81614 \| NIPA2 \| DISEASES 57142 \| RTN4 \| DISEASES 1576 \| CYP3A4 \| DISEASES 3363 \| HTR7 \| DISEASES 23583 \| SMUG1 \| DISEASES 391 \| RHOG \| DISEASES 4697 \| NDUFA4 \| DISEASES 6609 \| SMPD1 \| DISEASES 4128 \| MAOA \| DISEASES 84062 \| DTNBP1 \| DISEASES 1544 \| CYP1A2 \| DISEASES 1861 \| TOR1A \| DISEASES 6904 \| TBCD \| DISEASES 3359 \| HTR3A \| DISEASES 122786 \| FRMD6 \| DISEASES 200734 \| SPRED2 \| DISEASES 26052 \| DNM3 \| DISEASES 8822 \| FGF17 \| DISEASES 8936 \| WASF1 \| DISEASES 387129 \| NPSR1 \| DISEASES 23230 \| VPS13A \| DISEASES 1565 \| CYP2D6 \| DISEASES 4916 \| NTRK3 \| DISEASES 23245 \| ASTN2 \| DISEASES 1312 \| COMT \| DISEASES 460 \| ASTN1 \| DISEASES 26047 \| CNTNAP2 \| DISEASES 1813 \| DRD2 \| DISEASES 65217 \| PCDH15 \| DISEASES 9722 \| NOS1AP \| DISEASES 83259 \| PCDH11Y \| DISEASES 88 \| ACTN2 \| DISEASES 2058 \| EPRS \| DISEASES 25896 \| INTS7 \| DISEASES 1118 \| CHIT1 \| DISEASES 64222 \| TOR3A \| DISEASES 114792 \| KLHL32 \| DISEASES 1268 \| CNR1 \| DISEASES 3351 \| HTR1B \| DISEASES 278 \| AMY1C \| DISEASES 276 \| AMY1A \| DISEASES 115004 \| MB21D1 \| DISEASES 2332 \| FMR1 \| DISEASES 1486 \| CTBS \| DISEASES 10479 \| SLC9A6 \| DISEASES 81030 \| ZBP1 \| DISEASES 1557 \| CYP2C19 \| DISEASES 11128 \| POLR3A \| DISEASES 2899 \| GRIK3 \| DISEASES 27328 \| PCDH11X \| DISEASES 8879 \| SGPL1 \| DISEASES 22839 \| DLGAP4 \| DISEASES 22954 \| TRIM32 \| DISEASES 2914 \| GRM4 \| DISEASES 57134 \| MAN1C1 \| DISEASES 712 \| C1QA \| DISEASES 4814 \| NINJ1 \| DISEASES 4958 \| OMD \| DISEASES 267012 \| DAOA \| DISEASES 4795 \| NFKBIL1 \| DISEASES 23412 \| COMMD3 \| DISEASES 4340 \| MOG \| DISEASES 10082 \| GPC6 \| DISEASES 26050 \| SLITRK5 \| DISEASES 114798 \| SLITRK1 \| DISEASES 80036 \| TRPM3 \| DISEASES 4129 \| MAOB \| DISEASES 22903 \| BTBD3 \| DISEASES 3356 \| HTR2A \| DISEASES 2625 \| GATA3 \| DISEASES 22836 \| RHOBTB3 \| DISEASES 390598 \| SKOR1 \| DISEASES 551 \| AVP \| DISEASES 8544 \| PIR \| DISEASES 23081 \| KDM4C \| DISEASES 105 \| ADARB2 \| DISEASES 192668 \| CYS1 \| DISEASES 116448 \| OLIG1 \| DISEASES 200909 \| HTR3D \| DISEASES 2298 \| FOXD4 \| DISEASES 4487 \| MSX1 \| DISEASES 1814 \| DRD3 \| DISEASES 6263 \| RYR3 \| DISEASES 23365 \| ARHGEF12 \| DISEASES 594857 \| NPS \| DISEASES 2897 \| GRIK1 \| DISEASES 55209 \| SETD5 \| DISEASES 114781 \| BTBD9 \| DISEASES 25983 \| NGDN \| DISEASES 8604 \| SLC25A12 \| DISEASES 10163 \| WASF2 \| DISEASES 2898 \| GRIK2 \| DISEASES 4908 \| NTF3 \| DISEASES 7124 \| TNF \| DISEASES 8910 \| SGCE \| DISEASES 9228 \| DLGAP2 \| DISEASES 5087 \| PBX1 \| DISEASES 1139 \| CHRNA7 \| DISEASES 2668 \| GDNF \| DISEASES 1154 \| CISH \| DISEASES 2566 \| GABRG2 \| DISEASES 627 \| BDNF \| DISEASES 10046 \| MAMLD1 \| DISEASES 1496 \| CTNNA2 \| DISEASES 266553 \| OFCC1 \| DISEASES 9152 \| SLC6A5 \| DISEASES 10846 \| PDE10A \| DISEASES 4212 \| MEIS2 \| DISEASES 91056 \| AP5B1 \| DISEASES 820 \| CAMP \| DISEASES 102723508 \| KANTR \| DISEASES 7955 \| RNF217-AS1 \| DISEASES
Locus	(Waiting for update.)

Disease ID	277
Disease	obsessive-compulsive disorder
Integrated Phenotype	(Waiting for update.)
Text Mined Phenotype	HPO \| Name \| Sentences' Count(Total Phenotypes:34) HP:0000739 \| Anxiety \| 11 HP:0000716 \| Depression \| 8 HP:0012075 \| Personality disorder \| 7 HP:0100033 \| Tic disorder \| 6 HP:0100753 \| Schizophrenia \| 4 HP:0007302 \| Bipolar disorder \| 4 HP:0100710 \| Impulsivity \| 3 HP:0002500 \| Leukoaraiosis \| 3 HP:0000733 \| Repetitive movements \| 2 HP:0100543 \| Cognitive deficits \| 2 HP:0000756 \| Fear of open spaces \| 2 HP:0100754 \| Mania \| 2 HP:0003765 \| Psoriasis \| 1 HP:0012167 \| Trichotillomania \| 1 HP:0000717 \| Autism \| 1 HP:0001263 \| Developmental retardation \| 1 HP:0010636 \| Schizencephaly \| 1 HP:0000738 \| Sensory hallucination \| 1 HP:0000752 \| Hyperactive behavior \| 1 HP:0000708 \| Behavioral problems \| 1 HP:0012531 \| Pain \| 1 HP:0030880 \| Raynaud phenomenon \| 1 HP:0010553 \| Oculogyric crisis \| 1 HP:0100785 \| Insomnia \| 1 HP:0002063 \| Muscle rigidity \| 1 HP:0007018 \| Attention deficits \| 1 HP:0030050 \| Narcolepsy \| 1 HP:0000709 \| Psychosis \| 1 HP:0001249 \| Mental retardation \| 1 HP:0002067 \| Bradykinesia \| 1 HP:0011856 \| Pica \| 1 HP:0012532 \| Chronic pain \| 1 HP:0012154 \| Anhedonia \| 1 HP:0002389 \| Large cavum septi pellucidi \| 1

Disease ID	277
Disease	obsessive-compulsive disorder
Manually Symptom	(Waiting for update.)
Text Mined Symptom	UMLS \| Name \| Sentences' Count(Total Symptoms:12) C0003467 \| anxiety \| 8 C0011570 \| depression \| 8 C0009595 \| obsessive-compulsive personality disorder \| 3 C0235169 \| excitability \| 2 C0031212 \| personality disorders \| 2 C0033975 \| psychotic disorders \| 1 C0233565 \| bradykinesia \| 1 C0018524 \| hallucinations \| 1 C0013473 \| eating disorders \| 1 C0679466 \| cognitive deficits \| 1 C0815110 \| perfectionism \| 1 C0002020 \| alexithymia \| 1

Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)

All Snps(Total Genotypes:52)
snpId	pubmedId	geneId	geneSymbol	diseaseId	sourceId	sentence	score	Year	geneSymbol_dbSNP	CHROMOSOME	POS	REF	ALT
rs1000592	23928294	200909	HTR3D	umls:C0028768	BeFree	The case-control analyses revealed a nominal significant association of the HTR3D variant rs1000592 (p.H52R) with OCD (p=0.029) which was also evident after combination of the case-control and the trio-results (p=0.024).	0.000271442	2013	NA	2	118939624	C	A
rs1000952	23928294	200909	HTR3D	umls:C0028768	BeFree	The case-control analyses revealed a nominal significant association of the HTR3D variant rs1000592 (p.H52R) with OCD (p=0.029) which was also evident after combination of the case-control and the trio-results (p=0.024).	0.000271442	2013	HTR3D	3	184038034	G	T,A
rs10070190	23337130	1007	CDH9	umls:C0028768	BeFree	Five SNPs achieved 0.004 (the nominal p-value expected by chance), 3 with empirical significant p-values (rs10070190 (CDH9) p = 1 × 10(-3), rs4825476 (GRIA3) p = 4 × 10(-4), and rs1074815 (TPH2) p = 8 × 10(-4)) and 2 additional polymorphisms showing nominal significance (rs2834070 (OLIG2) p = 2 × 10(-3) and rs11783752 (SCL18A1) p = 3 × 10(-3)), were found to be related to both AN and OCD.	0.000271442	2012	NA	5	26866262	G	A
rs10070190	23337130	10215	OLIG2	umls:C0028768	BeFree	Five SNPs achieved 0.004 (the nominal p-value expected by chance), 3 with empirical significant p-values (rs10070190 (CDH9) p = 1 × 10(-3), rs4825476 (GRIA3) p = 4 × 10(-4), and rs1074815 (TPH2) p = 8 × 10(-4)) and 2 additional polymorphisms showing nominal significance (rs2834070 (OLIG2) p = 2 × 10(-3) and rs11783752 (SCL18A1) p = 3 × 10(-3)), were found to be related to both AN and OCD.	0.000542884	2012	NA	5	26866262	G	A
rs10070190	23337130	2892	GRIA3	umls:C0028768	BeFree	Five SNPs achieved 0.004 (the nominal p-value expected by chance), 3 with empirical significant p-values (rs10070190 (CDH9) p = 1 × 10(-3), rs4825476 (GRIA3) p = 4 × 10(-4), and rs1074815 (TPH2) p = 8 × 10(-4)) and 2 additional polymorphisms showing nominal significance (rs2834070 (OLIG2) p = 2 × 10(-3) and rs11783752 (SCL18A1) p = 3 × 10(-3)), were found to be related to both AN and OCD.	0.000271442	2012	NA	5	26866262	G	A
rs10070190	23337130	121278	TPH2	umls:C0028768	BeFree	Five SNPs achieved 0.004 (the nominal p-value expected by chance), 3 with empirical significant p-values (rs10070190 (CDH9) p = 1 × 10(-3), rs4825476 (GRIA3) p = 4 × 10(-4), and rs1074815 (TPH2) p = 8 × 10(-4)) and 2 additional polymorphisms showing nominal significance (rs2834070 (OLIG2) p = 2 × 10(-3) and rs11783752 (SCL18A1) p = 3 × 10(-3)), were found to be related to both AN and OCD.	0.001357209	2012	NA	5	26866262	G	A
rs1074815	23337130	2892	GRIA3	umls:C0028768	BeFree	Five SNPs achieved 0.004 (the nominal p-value expected by chance), 3 with empirical significant p-values (rs10070190 (CDH9) p = 1 × 10(-3), rs4825476 (GRIA3) p = 4 × 10(-4), and rs1074815 (TPH2) p = 8 × 10(-4)) and 2 additional polymorphisms showing nominal significance (rs2834070 (OLIG2) p = 2 × 10(-3) and rs11783752 (SCL18A1) p = 3 × 10(-3)), were found to be related to both AN and OCD.	0.000271442	2012	NA	NA	NA	NA	NA
rs1074815	23337130	1007	CDH9	umls:C0028768	BeFree	Five SNPs achieved 0.004 (the nominal p-value expected by chance), 3 with empirical significant p-values (rs10070190 (CDH9) p = 1 × 10(-3), rs4825476 (GRIA3) p = 4 × 10(-4), and rs1074815 (TPH2) p = 8 × 10(-4)) and 2 additional polymorphisms showing nominal significance (rs2834070 (OLIG2) p = 2 × 10(-3) and rs11783752 (SCL18A1) p = 3 × 10(-3)), were found to be related to both AN and OCD.	0.000271442	2012	NA	NA	NA	NA	NA
rs1074815	23337130	121278	TPH2	umls:C0028768	BeFree	Five SNPs achieved 0.004 (the nominal p-value expected by chance), 3 with empirical significant p-values (rs10070190 (CDH9) p = 1 × 10(-3), rs4825476 (GRIA3) p = 4 × 10(-4), and rs1074815 (TPH2) p = 8 × 10(-4)) and 2 additional polymorphisms showing nominal significance (rs2834070 (OLIG2) p = 2 × 10(-3) and rs11783752 (SCL18A1) p = 3 × 10(-3)), were found to be related to both AN and OCD.	0.001357209	2012	NA	NA	NA	NA	NA
rs1074815	23337130	10215	OLIG2	umls:C0028768	BeFree	Five SNPs achieved 0.004 (the nominal p-value expected by chance), 3 with empirical significant p-values (rs10070190 (CDH9) p = 1 × 10(-3), rs4825476 (GRIA3) p = 4 × 10(-4), and rs1074815 (TPH2) p = 8 × 10(-4)) and 2 additional polymorphisms showing nominal significance (rs2834070 (OLIG2) p = 2 × 10(-3) and rs11783752 (SCL18A1) p = 3 × 10(-3)), were found to be related to both AN and OCD.	0.000542884	2012	NA	NA	NA	NA	NA
rs11783752	23337130	2892	GRIA3	umls:C0028768	BeFree	Five SNPs achieved 0.004 (the nominal p-value expected by chance), 3 with empirical significant p-values (rs10070190 (CDH9) p = 1 × 10(-3), rs4825476 (GRIA3) p = 4 × 10(-4), and rs1074815 (TPH2) p = 8 × 10(-4)) and 2 additional polymorphisms showing nominal significance (rs2834070 (OLIG2) p = 2 × 10(-3) and rs11783752 (SCL18A1) p = 3 × 10(-3)), were found to be related to both AN and OCD.	0.000271442	2012	NA	8	20192013	G	A
rs11783752	23337130	10215	OLIG2	umls:C0028768	BeFree	Five SNPs achieved 0.004 (the nominal p-value expected by chance), 3 with empirical significant p-values (rs10070190 (CDH9) p = 1 × 10(-3), rs4825476 (GRIA3) p = 4 × 10(-4), and rs1074815 (TPH2) p = 8 × 10(-4)) and 2 additional polymorphisms showing nominal significance (rs2834070 (OLIG2) p = 2 × 10(-3) and rs11783752 (SCL18A1) p = 3 × 10(-3)), were found to be related to both AN and OCD.	0.000542884	2012	NA	8	20192013	G	A
rs11783752	23337130	1007	CDH9	umls:C0028768	BeFree	Five SNPs achieved 0.004 (the nominal p-value expected by chance), 3 with empirical significant p-values (rs10070190 (CDH9) p = 1 × 10(-3), rs4825476 (GRIA3) p = 4 × 10(-4), and rs1074815 (TPH2) p = 8 × 10(-4)) and 2 additional polymorphisms showing nominal significance (rs2834070 (OLIG2) p = 2 × 10(-3) and rs11783752 (SCL18A1) p = 3 × 10(-3)), were found to be related to both AN and OCD.	0.000271442	2012	NA	8	20192013	G	A
rs11783752	23337130	121278	TPH2	umls:C0028768	BeFree	Five SNPs achieved 0.004 (the nominal p-value expected by chance), 3 with empirical significant p-values (rs10070190 (CDH9) p = 1 × 10(-3), rs4825476 (GRIA3) p = 4 × 10(-4), and rs1074815 (TPH2) p = 8 × 10(-4)) and 2 additional polymorphisms showing nominal significance (rs2834070 (OLIG2) p = 2 × 10(-3) and rs11783752 (SCL18A1) p = 3 × 10(-3)), were found to be related to both AN and OCD.	0.001357209	2012	NA	8	20192013	G	A
rs1844437	21302353	345651	ACTBL2	umls:C0028768	GAD	[Genome-wide association study of hoarding traits.]	0.002367032	2011	NA	5	58025127	C	G
rs25531	23630162	3938	LCT	umls:C0028768	BeFree	Likewise, the higher expressing LAC haplotype (5-HTTLPR/rs25531/rs25532) was more frequent in TD probands than in controls (P = 0.024; OR, 1.33) and also in the TD alone group versus the TD plus OCD group (P = 0.0013; OR, 2.14).	0.000271442	2013	SLC6A4;LOC105371720	17	30237328	T	C
rs25531	23630162	6532	SLC6A4	umls:C0028768	BeFree	Likewise, the higher expressing LAC haplotype (5-HTTLPR/rs25531/rs25532) was more frequent in TD probands than in controls (P = 0.024; OR, 1.33) and also in the TD alone group versus the TD plus OCD group (P = 0.0013; OR, 2.14).	0.176174788	2013	SLC6A4;LOC105371720	17	30237328	T	C
rs25532	23630162	3938	LCT	umls:C0028768	BeFree	Likewise, the higher expressing LAC haplotype (5-HTTLPR/rs25531/rs25532) was more frequent in TD probands than in controls (P = 0.024; OR, 1.33) and also in the TD alone group versus the TD plus OCD group (P = 0.0013; OR, 2.14).	0.000271442	2013	SLC6A4;LOC105371720	17	30237152	G	A
rs25532	23630162	6532	SLC6A4	umls:C0028768	BeFree	Likewise, the higher expressing LAC haplotype (5-HTTLPR/rs25531/rs25532) was more frequent in TD probands than in controls (P = 0.024; OR, 1.33) and also in the TD alone group versus the TD plus OCD group (P = 0.0013; OR, 2.14).	0.176174788	2013	SLC6A4;LOC105371720	17	30237152	G	A
rs2834070	23337130	2892	GRIA3	umls:C0028768	BeFree	Five SNPs achieved 0.004 (the nominal p-value expected by chance), 3 with empirical significant p-values (rs10070190 (CDH9) p = 1 × 10(-3), rs4825476 (GRIA3) p = 4 × 10(-4), and rs1074815 (TPH2) p = 8 × 10(-4)) and 2 additional polymorphisms showing nominal significance (rs2834070 (OLIG2) p = 2 × 10(-3) and rs11783752 (SCL18A1) p = 3 × 10(-3)), were found to be related to both AN and OCD.	0.000271442	2012	LOC105372784	21	33015144	G	T
rs2834070	23337130	1007	CDH9	umls:C0028768	BeFree	Five SNPs achieved 0.004 (the nominal p-value expected by chance), 3 with empirical significant p-values (rs10070190 (CDH9) p = 1 × 10(-3), rs4825476 (GRIA3) p = 4 × 10(-4), and rs1074815 (TPH2) p = 8 × 10(-4)) and 2 additional polymorphisms showing nominal significance (rs2834070 (OLIG2) p = 2 × 10(-3) and rs11783752 (SCL18A1) p = 3 × 10(-3)), were found to be related to both AN and OCD.	0.000271442	2012	LOC105372784	21	33015144	G	T
rs2834070	23337130	10215	OLIG2	umls:C0028768	BeFree	Five SNPs achieved 0.004 (the nominal p-value expected by chance), 3 with empirical significant p-values (rs10070190 (CDH9) p = 1 × 10(-3), rs4825476 (GRIA3) p = 4 × 10(-4), and rs1074815 (TPH2) p = 8 × 10(-4)) and 2 additional polymorphisms showing nominal significance (rs2834070 (OLIG2) p = 2 × 10(-3) and rs11783752 (SCL18A1) p = 3 × 10(-3)), were found to be related to both AN and OCD.	0.000542884	2012	LOC105372784	21	33015144	G	T
rs2834070	23337130	121278	TPH2	umls:C0028768	BeFree	Five SNPs achieved 0.004 (the nominal p-value expected by chance), 3 with empirical significant p-values (rs10070190 (CDH9) p = 1 × 10(-3), rs4825476 (GRIA3) p = 4 × 10(-4), and rs1074815 (TPH2) p = 8 × 10(-4)) and 2 additional polymorphisms showing nominal significance (rs2834070 (OLIG2) p = 2 × 10(-3) and rs11783752 (SCL18A1) p = 3 × 10(-3)), were found to be related to both AN and OCD.	0.001357209	2012	LOC105372784	21	33015144	G	T
rs28521337	19370765	4916	NTRK3	umls:C0028768	BeFree	We have found the C allele of rs28521337, located in a functional target site for miR-485-3p in the truncated isoform of NTRK3, to be significantly associated with the hoarding phenotype of OCD.	0.003181358	2009	NTRK3	15	87978049	C	G
rs28521337	19370765	574436	MIR485	umls:C0028768	BeFree	We have found the C allele of rs28521337, located in a functional target site for miR-485-3p in the truncated isoform of NTRK3, to be significantly associated with the hoarding phenotype of OCD.	0.000271442	2009	NTRK3	15	87978049	C	G
rs2883187	24291483	627	BDNF	umls:C0028768	BeFree	The role of the brain-derived neurotrophic factor SNP rs2883187 in the phenotypic expression of obsessive-compulsive disorder.	0.139802782	2013	BDNF	11	27719545	G	A
rs297941	22889921	101927292	LOC101927292	umls:C0028768	GWASCAT	Genome-wide association study of obsessive-compulsive disorder.	0.12	2014	LOC101927292	12	49925303	A	G
rs301443	20410850	6505	SLC1A1	umls:C0028768	BeFree	Interestingly, the strongest association in OCD has been found at rs301443 (P=0.000067) residing between SLC1A1 and JMJD2C at 9p24.	0.018078323	2010	NA	9	4594919	C	G
rs324981	23680103	387129	NPSR1	umls:C0028768	BeFree	The functional coding variant Asn107Ile of the neuropeptide S receptor gene (NPSR1) influences age at onset of obsessive-compulsive disorder.	0.000271442	2014	NPSR1;NPSR1-AS1	7	34778501	A	T
rs3747767	21302353	167691	LCA5	umls:C0028768	GAD	[Genome-wide association study of hoarding traits.]	0.002367032	2011	LOC105377866	6	79547564	C	A
rs386602118	19219856	627	BDNF	umls:C0028768	BeFree	The role of the brain-derived neurotrophic factor (BDNF) val66met variant in the phenotypic expression of obsessive-compulsive disorder (OCD).	0.139802782	2009	NA	NA	NA	NA	NA
rs386602118	22911909	627	BDNF	umls:C0028768	BeFree	Brain-derived neurotrophic factor gene Val66Met polymorphism and cognitive function in obsessive-compulsive disorder.	0.139802782	2012	NA	NA	NA	NA	NA
rs386602118	17853300	627	BDNF	umls:C0028768	BeFree	Investigating the role of the brain-derived neurotrophic factor (BDNF) val66met variant in obsessive-compulsive disorder (OCD).	0.139802782	2008	NA	NA	NA	NA	NA
rs386602276	18191318	3356	HTR2A	umls:C0028768	BeFree	The purpose of this study is to investigate the association between four serotonergic polymorphisms (STin2 VNTR and 5-HTTLPR of the SLC6A4 gene, and A-1438G (rs6311) and T102C (rs6313) of the HTR2A gene) and OCD.	0.140726728	2008	NA	NA	NA	NA	NA
rs386602276	12927326	3356	HTR2A	umls:C0028768	BeFree	T102C and -1438 G/A polymorphisms of the 5-HT2A receptor gene in Turkish patients with obsessive-compulsive disorder.	0.140726728	2003	NA	NA	NA	NA	NA
rs386602276	16910371	3356	HTR2A	umls:C0028768	BeFree	Both genotypic and allelic distributions of the 5-HT receptor 2A (5-HT2A) T102C variant were found to be significantly different between the TTM and control subjects (p=0.028 and p=0.024, respectively), and a trend towards significance was noted between the TTM and OCD subjects (p=0.084 and p=0.080 for genotype and allele analyses, respectively), with the T102T-genotype found to confer susceptibility to the development of TTM.	0.140726728	2006	NA	NA	NA	NA	NA
rs4680	17805313	1312	COMT	umls:C0028768	BeFree	Many of these differences are unconfirmed or minor, but some appear to be of reasonable robustness and magnitude; eg the functional Val(158)Met polymorphism in COMT is associated with obsessive-compulsive disorder in men, with anxiety phenotypes in women, and has a greater impact on cognitive function in boys than girls.	0.034352361	2008	COMT;MIR4761	22	19963748	G	A
rs4680	16187774	1312	COMT	umls:C0028768	BeFree	In subjects of Afrikaner descent, the L/L genotype of the COMT Val158Met polymorphism was significantly more common in the OCD hoarding group, with a preponderance of low activity alleles, compared with nonhoarding patients and controls.	0.034352361	2005	COMT;MIR4761	22	19963748	G	A
rs4680	19398820	1312	COMT	umls:C0028768	BeFree	The data here are consistent with previous work delineating the different symptom subtypes of OCD, also with previous work suggesting that the Met/Met (L/L) genotype of the COMT Val158Met polymorphism may be associated with anxiety symptoms, as well as with previous work suggesting that dopaminergic genes may be particularly important in early-onset OCD.	0.034352361	2008	COMT;MIR4761	22	19963748	G	A
rs4680	16043283	1312	COMT	umls:C0028768	BeFree	COMT Val158Met polymorphism in schizophrenia with obsessive-compulsive disorder: a case-control study.	0.034352361	2005	COMT;MIR4761	22	19963748	G	A
rs4825476	23337130	121278	TPH2	umls:C0028768	BeFree	Five SNPs achieved 0.004 (the nominal p-value expected by chance), 3 with empirical significant p-values (rs10070190 (CDH9) p = 1 × 10(-3), rs4825476 (GRIA3) p = 4 × 10(-4), and rs1074815 (TPH2) p = 8 × 10(-4)) and 2 additional polymorphisms showing nominal significance (rs2834070 (OLIG2) p = 2 × 10(-3) and rs11783752 (SCL18A1) p = 3 × 10(-3)), were found to be related to both AN and OCD.	0.001357209	2012	GRIA3	X	123307628	G	A
rs4825476	23337130	1007	CDH9	umls:C0028768	BeFree	Five SNPs achieved 0.004 (the nominal p-value expected by chance), 3 with empirical significant p-values (rs10070190 (CDH9) p = 1 × 10(-3), rs4825476 (GRIA3) p = 4 × 10(-4), and rs1074815 (TPH2) p = 8 × 10(-4)) and 2 additional polymorphisms showing nominal significance (rs2834070 (OLIG2) p = 2 × 10(-3) and rs11783752 (SCL18A1) p = 3 × 10(-3)), were found to be related to both AN and OCD.	0.000271442	2012	GRIA3	X	123307628	G	A
rs4825476	23337130	2892	GRIA3	umls:C0028768	BeFree	Five SNPs achieved 0.004 (the nominal p-value expected by chance), 3 with empirical significant p-values (rs10070190 (CDH9) p = 1 × 10(-3), rs4825476 (GRIA3) p = 4 × 10(-4), and rs1074815 (TPH2) p = 8 × 10(-4)) and 2 additional polymorphisms showing nominal significance (rs2834070 (OLIG2) p = 2 × 10(-3) and rs11783752 (SCL18A1) p = 3 × 10(-3)), were found to be related to both AN and OCD.	0.000271442	2012	GRIA3	X	123307628	G	A
rs4825476	23337130	10215	OLIG2	umls:C0028768	BeFree	Five SNPs achieved 0.004 (the nominal p-value expected by chance), 3 with empirical significant p-values (rs10070190 (CDH9) p = 1 × 10(-3), rs4825476 (GRIA3) p = 4 × 10(-4), and rs1074815 (TPH2) p = 8 × 10(-4)) and 2 additional polymorphisms showing nominal significance (rs2834070 (OLIG2) p = 2 × 10(-3) and rs11783752 (SCL18A1) p = 3 × 10(-3)), were found to be related to both AN and OCD.	0.000542884	2012	GRIA3	X	123307628	G	A
rs6311	21874579	3356	HTR2A	umls:C0028768	BeFree	Pilot study on HTR2A promoter polymorphism, -1438G/A (rs6311) and a nearby copy number variation showed association with onset and severity in early onset obsessive-compulsive disorder.	0.140726728	2012	HTR2A	13	46897343	C	T
rs6311	17241828	3356	HTR2A	umls:C0028768	BeFree	Nominally significant association was found at the HTR2A rs6311 polymorphism in subjects with tic disorder and OCD (p = .05), replicating a previous finding in Tourette syndrome and OCD.	0.140726728	2007	HTR2A	13	46897343	C	T
rs6311	18191318	3356	HTR2A	umls:C0028768	BeFree	The purpose of this study is to investigate the association between four serotonergic polymorphisms (STin2 VNTR and 5-HTTLPR of the SLC6A4 gene, and A-1438G (rs6311) and T102C (rs6313) of the HTR2A gene) and OCD.	0.140726728	2008	HTR2A	13	46897343	C	T
rs6313	12927326	3356	HTR2A	umls:C0028768	BeFree	T102C and -1438 G/A polymorphisms of the 5-HT2A receptor gene in Turkish patients with obsessive-compulsive disorder.	0.140726728	2003	HTR2A	13	46895805	G	A
rs6313	18191318	3356	HTR2A	umls:C0028768	BeFree	The purpose of this study is to investigate the association between four serotonergic polymorphisms (STin2 VNTR and 5-HTTLPR of the SLC6A4 gene, and A-1438G (rs6311) and T102C (rs6313) of the HTR2A gene) and OCD.	0.140726728	2008	HTR2A	13	46895805	G	A
rs6313	16910371	3356	HTR2A	umls:C0028768	BeFree	Both genotypic and allelic distributions of the 5-HT receptor 2A (5-HT2A) T102C variant were found to be significantly different between the TTM and control subjects (p=0.028 and p=0.024, respectively), and a trend towards significance was noted between the TTM and OCD subjects (p=0.084 and p=0.080 for genotype and allele analyses, respectively), with the T102T-genotype found to confer susceptibility to the development of TTM.	0.140726728	2006	HTR2A	13	46895805	G	A
rs6766410	23928294	170572	HTR3C	umls:C0028768	BeFree	In male subjects, the variant rs6766410 (p.N163K) located in the HTR3C was significantly associated with OCD (p=0.007).	0.000271442	2013	HTR3C	3	184056974	C	A
rs945032	19086053	624	BDKRB2	umls:C0028768	BeFree	Remarkably, a functional SNP, rs945032, located in the promoter region of the bradykinin receptor B2 gene (BDKRB2) was associated to three disorders (panic disorder, substance abuse, and bipolar disorder), and two additional BDKRB2 SNPs to obsessive-compulsive disorder and major depression, providing evidence for common variants of susceptibility to several related psychiatric disorders.	0.000271442	2009	BDKRB2	14	96204324	T	C

GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)

GWASdb Snp Trait(Total Genotypes:53)
CHR	POS	SNPID	REF	ALT	ORI_SNPID	PMID	P_VALUE	P_VALUE_TEXT	OR/BETA	CI95_TEXT	GWAS_INITIAL_SAMPLE_SIZE	SUB_POPULATION	SUPER_POPULATION	GWAS_TRAIT	HPO_ID	HPO_TERM	DO_ID	DO_TERM	MESH_ID	MESH_TERM	EFO_ID	EFO_TERM	DOLITE_TERM	RISK_ALLELE	PUBLICATION_TYPE	AA	GENE_SYMBOL	TYPE	REFGENE
1	185201061	rs12096987	T	C	rs12096987	24821223	8.87E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs12096987-C	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	C
2	44358504	rs7593878	A	C	rs7593878	24821223	5.44E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs7593878-C	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	A
2	44358504	rs7593878	A	C	rs7593878	24821223	5.44E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs7593878-C	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	A
2	182189405	rs16867406	C	T	rs16867406	24821223	6.10E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs16867406-T	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	C
2	182189405	rs16867406	C	T	rs16867406	24821223	6.10E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs16867406-T	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	C
3	176352763	rs838209	A	G	rs838209	24821223	4.14E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs838209-C	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	T
3	179531062	rs9845643	A	G	rs9845643	24821223	8.58E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs9845643-G	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	G
4	75216365	rs16851014	G	A	rs16851014	24821223	7.89E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs16851014-A	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	G
4	75216365	rs16851014	G	A	rs16851014	24821223	7.89E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs16851014-A	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	G
4	157279663	rs1532154	T	C	rs1532154	24821223	2.22E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs1532154-C	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	T
5	24922789	rs6452234	G	A	rs6452234	24821223	1.13E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs6452234-A	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	A
5	25572301	rs6876547	T	G	rs6876547	24821223	2.00E-06	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs6876547-G	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	G
5	168653502	rs17735629	T	C	rs17735629	24821223	5.03E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs17735629-C	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	T
5	168653502	rs17735629	T	C	rs17735629	24821223	5.03E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs17735629-C	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	T
6	104445367	rs9499708	C	T	rs9499708	22889921	3.00E-06	NA	1.2	NA	1,279 European ancestry cases; 5,139 European ancestry controls; 93 South African Afrikaner cases; 158 South African Afrikaner controls; 93 Ashkenazi Jewish cases; 260 Ashkenazi Jewish controls; 299 European ancestry trios; 101 trios	NOPOP(101)	African Afrikaner(251)	South African(251)	European(6717)	Ashkenazi Jewish(353)	ALL(7673)	NOPOP(101)	MEA(353)	AFR(502)	EUR(6717)	ALL(7673)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder
6	133578733	rs973714	G	A	rs973714	24821223	7.44E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs973714-A	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	G
6	133578733	rs973714	G	A	rs973714	24821223	7.44E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs973714-A	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	G
7	54313171	rs13437953	C	A	rs13437953	24821223	9.69E-06	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs13437953-A	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	C
8	25634077	rs2278144	G	A	rs2278144	24821223	3.94E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs2278144-T	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	C
8	26833198	rs12547343	C	A	rs12547343	24821223	5.38E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs12547343-A	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	A
8	26833198	rs12547343	C	A	rs12547343	24821223	5.38E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs12547343-A	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	A
8	80266553	rs7462051	G	A	rs7462051	24821223	1.69E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs7462051-A	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	G
8	126303493	rs7003102	A	G	rs7003102	24821223	5.14E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs7003102-G	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	A
8	126303493	rs7003102	A	G	rs7003102	24821223	5.14E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs7003102-G	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	A
8	130620813	rs7005206	A	G	rs7005206	24821223	9.13E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs7005206-A	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	G
9	11683901	rs2821204	C	T	rs2821204	24821223	2.89E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs2821204-G	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	G
9	11890045	rs4401971	A	G	rs4401971	24821223	4.00E-07	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs4401971-A	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	G
9	71211200	rs2183738	C	T	rs2183738	24821223	8.73E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs2183738-G	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	G
9	92077132	rs11265908	T	C	rs11265908	24821223	8.60E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs11265908-C	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	C
10	17065067	rs3902042	T	C	rs3902042	24821223	7.71E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs3902042-T	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	C
10	17065067	rs3902042	T	C	rs3902042	24821223	7.71E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs3902042-T	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	C
10	97109019	rs10882583	A	G	rs10882583	24821223	3.56E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs10882583-A	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	A
11	79811268	rs509876	G	A	rs509876	24821223	2.29E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs509876-G	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	A
12	50319086	rs297941	A	G	rs297941	22889921	5.00E-07	NA	1.23	NA	1,279 European ancestry cases; 5,139 European ancestry controls; 93 South African Afrikaner cases; 158 South African Afrikaner controls; 93 Ashkenazi Jewish cases; 260 Ashkenazi Jewish controls; 299 European ancestry trios; 101 trios	NOPOP(101)	African Afrikaner(251)	South African(251)	European(6717)	Ashkenazi Jewish(353)	ALL(7673)	NOPOP(101)	MEA(353)	AFR(502)	EUR(6717)	ALL(7673)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder
13	35095884	rs9541148	C	T	rs9541148	24821223	6.73E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs9541148-C	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	C
13	35095884	rs9541148	C	T	rs9541148	24821223	6.73E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs9541148-C	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	C
13	72688774	rs9652236	G	T	rs9652236	22889921	5.00E-06	NA	1.4	NA	1,279 European ancestry cases; 5,139 European ancestry controls; 93 South African Afrikaner cases; 158 South African Afrikaner controls; 93 Ashkenazi Jewish cases; 260 Ashkenazi Jewish controls; 299 European ancestry trios; 101 trios	NOPOP(101)	African Afrikaner(251)	South African(251)	European(6717)	Ashkenazi Jewish(353)	ALL(7673)	NOPOP(101)	MEA(353)	AFR(502)	EUR(6717)	ALL(7673)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder
14	24039559	rs10149510	C	T	rs10149510	24821223	1.49E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs10149510-T	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	T
15	37247722	rs8026755	C	A	rs8026755	24821223	4.03E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs8026755-A	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	C
16	19713882	rs1544352	A	G	rs1544352	24821223	1.94E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs1544352-C	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	C
18	50040561	rs1671253	G	A	rs1671253	24821223	7.04E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs1671253-T	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	T
18	50040561	rs1671253	G	A	rs1671253	24821223	7.04E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs1671253-T	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	T
20	11995427	rs6131293	A	G	rs6131293	22889921	3.67E-07	NA	NA	NA	1,279 European ancestry cases; 5,139 European ancestry controls; 93 South African Afrikaner cases; 158 South African Afrikaner controls; 93 Ashkenazi Jewish cases; 260 Ashkenazi Jewish controls; 299 European ancestry trios; 101 trios	NOPOP(101)	African Afrikaner(251)	South African(251)	European(6717)	Ashkenazi Jewish(353)	ALL(7673)	NOPOP(101)	MEA(353)	AFR(502)	EUR(6717)	ALL(7673)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder
20	11996267	rs6131295	G	A	rs6131295	22889921	3.84E-08	NA	NA	NA	1,279 European ancestry cases; 5,139 European ancestry controls; 93 South African Afrikaner cases; 158 South African Afrikaner controls; 93 Ashkenazi Jewish cases; 260 Ashkenazi Jewish controls; 299 European ancestry trios; 101 trios	NOPOP(101)	African Afrikaner(251)	South African(251)	European(6717)	Ashkenazi Jewish(353)	ALL(7673)	NOPOP(101)	MEA(353)	AFR(502)	EUR(6717)	ALL(7673)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder
20	11999145	rs6109227	A	T	rs6109227	22889921	2.11E-07	NA	NA	NA	1,279 European ancestry cases; 5,139 European ancestry controls; 93 South African Afrikaner cases; 158 South African Afrikaner controls; 93 Ashkenazi Jewish cases; 260 Ashkenazi Jewish controls; 299 European ancestry trios; 101 trios	NOPOP(101)	African Afrikaner(251)	South African(251)	European(6717)	Ashkenazi Jewish(353)	ALL(7673)	NOPOP(101)	MEA(353)	AFR(502)	EUR(6717)	ALL(7673)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder
20	12001554	rs6033274	C	T	rs6033274	22889921	1.66E-06	NA	NA	NA	1,279 European ancestry cases; 5,139 European ancestry controls; 93 South African Afrikaner cases; 158 South African Afrikaner controls; 93 Ashkenazi Jewish cases; 260 Ashkenazi Jewish controls; 299 European ancestry trios; 101 trios	NOPOP(101)	African Afrikaner(251)	South African(251)	European(6717)	Ashkenazi Jewish(353)	ALL(7673)	NOPOP(101)	MEA(353)	AFR(502)	EUR(6717)	ALL(7673)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder
20	12003383	rs6134437	T	C	rs6134437	22889921	1.97E-06	NA	NA	NA	1,279 European ancestry cases; 5,139 European ancestry controls; 93 South African Afrikaner cases; 158 South African Afrikaner controls; 93 Ashkenazi Jewish cases; 260 Ashkenazi Jewish controls; 299 European ancestry trios; 101 trios	NOPOP(101)	African Afrikaner(251)	South African(251)	European(6717)	Ashkenazi Jewish(353)	ALL(7673)	NOPOP(101)	MEA(353)	AFR(502)	EUR(6717)	ALL(7673)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder
20	12003410	rs6134438	G	A	rs6134438	22889921	2.83E-06	NA	NA	NA	1,279 European ancestry cases; 5,139 European ancestry controls; 93 South African Afrikaner cases; 158 South African Afrikaner controls; 93 Ashkenazi Jewish cases; 260 Ashkenazi Jewish controls; 299 European ancestry trios; 101 trios	NOPOP(101)	African Afrikaner(251)	South African(251)	European(6717)	Ashkenazi Jewish(353)	ALL(7673)	NOPOP(101)	MEA(353)	AFR(502)	EUR(6717)	ALL(7673)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder
20	12003484	rs6134439	G	A	rs6134439	22889921	1.97E-06	NA	NA	NA	1,279 European ancestry cases; 5,139 European ancestry controls; 93 South African Afrikaner cases; 158 South African Afrikaner controls; 93 Ashkenazi Jewish cases; 260 Ashkenazi Jewish controls; 299 European ancestry trios; 101 trios	NOPOP(101)	African Afrikaner(251)	South African(251)	European(6717)	Ashkenazi Jewish(353)	ALL(7673)	NOPOP(101)	MEA(353)	AFR(502)	EUR(6717)	ALL(7673)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder
20	16533162	rs16997877	T	C	rs16997877	24821223	8.68E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs16997877-C	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	T
20	37550935	rs10392	G	A	rs10392	24821223	2.87E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs10392-A	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	G
20	50712059	rs8120171	C	T	rs8120171	24821223	7.85E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs8120171-T	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	C
20	50712059	rs8120171	C	T	rs8120171	24821223	7.85E-05	NA	NA	NA	1,406 cases; 1,489 controls from 1,065 families; 192 cases; 1,984 controls	NOPOP(5071)	ALL(5071)	NOPOP(5071)	ALL(5071)	Obsessive-compulsive disorder	HPOID:0000722	Obsessive-compulsive behavior	DOID:10933	obsessive-compulsive disorder	D009771	Obsessive-Compulsive Disorder	NA	NA	Obsessive-compulsive disorder	rs8120171-T	Research Support, N.I.H., Extramural	Research Support, N.I.H., Intramural	C

Mapped by lexical matching(Total Items:0)
(Waiting for update.)

Mapped by homologous gene(Total Items:0)
(Waiting for update.)

Chemical(Total Drugs:22)
CUI	ChemicalName	ChemicalID	CasRN	DiseaseName	DiseaseID	DirectEvidence	PubMedIDs
C0028768	aripiprazole	D000068180	-	obsessive-compulsive disorder	MESH:D009771	marker/mechanism	17414263
C0028768	aripiprazole	D000068180	-	obsessive-compulsive disorder	MESH:D009771	therapeutic	19644230
C0028768	buspirone	D002065	36505-84-7	obsessive-compulsive disorder	MESH:D009771	marker/mechanism	2258456
C0028768	buspirone	D002065	36505-84-7	obsessive-compulsive disorder	MESH:D009771	therapeutic	1552034
C0028768	chlorpromazine	D002746	50-53-3	obsessive-compulsive disorder	MESH:D009771	marker/mechanism	8890690
C0028768	citalopram	D015283	59729-33-8	obsessive-compulsive disorder	MESH:D009771	therapeutic	12505824
C0028768	clonidine	D003000	4205-90-7	obsessive-compulsive disorder	MESH:D009771	therapeutic	1876628
C0028768	clozapine	D003024	5786-21-0	obsessive-compulsive disorder	MESH:D009771	marker/mechanism	10401913
C0028768	clozapine	D003024	5786-21-0	obsessive-compulsive disorder	MESH:D009771	therapeutic	19766686
C0028768	codeine	D003061	76-57-3	obsessive-compulsive disorder	MESH:D009771	marker/mechanism	2763855
C0028768	fluoxetine	D005473	54910-89-3	obsessive-compulsive disorder	MESH:D009771	marker/mechanism	1883009
C0028768	fluoxetine	D005473	54910-89-3	obsessive-compulsive disorder	MESH:D009771	therapeutic	10327925
C0028768	fluvoxamine	D016666	54739-18-3	obsessive-compulsive disorder	MESH:D009771	therapeutic	11098342
C0028768	methylphenidate	D008774	113-45-1	obsessive-compulsive disorder	MESH:D009771	marker/mechanism	10858915
C0028768	mirtazapine	C035133	-	obsessive-compulsive disorder	MESH:D009771	therapeutic	15491244
C0028768	levonorgestrel	D016912	797-63-7	obsessive-compulsive disorder	MESH:D009771	marker/mechanism	8601550
C0028768	nortriptyline	D009661	72-69-5	obsessive-compulsive disorder	MESH:D009771	therapeutic	17089931
C0028768	olanzapine	C076029	132539-06-1	obsessive-compulsive disorder	MESH:D009771	marker/mechanism	10327925
C0028768	olanzapine	C076029	132539-06-1	obsessive-compulsive disorder	MESH:D009771	therapeutic	11147933
C0028768	phentermine	D010645	122-09-8	obsessive-compulsive disorder	MESH:D009771	marker/mechanism	9829290
C0028768	tetrabenazine	D013747	58-46-8	obsessive-compulsive disorder	MESH:D009771	marker/mechanism	12355681
C0028768	ziprasidone	C092292	146939-27-7	obsessive-compulsive disorder	MESH:D009771	marker/mechanism	19644229

FDA approved drug and dosage information(Total Drugs:46)
DiseaseID	Drug_name	active_ingredients	strength	Dosage Form/Route	Marketing Status	TE code	RLD	RS
MESH:D009771	remeron	mirtazapine	15MG	TABLET;ORAL	Prescription	AB	Yes	Yes
MESH:D009771	daytrana	methylphenidate	10MG/9HR (1.1MG/HR)	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription	None	Yes	No
MESH:D009771	daytrana	methylphenidate	10MG/9HR (1.1MG/HR)	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription	None	Yes	No
MESH:D009771	daytrana	methylphenidate	10MG/9HR (1.1MG/HR)	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription	None	Yes	No
MESH:D009771	abilify	aripiprazole	10MG	TABLET;ORAL	Prescription	AB	Yes	Yes
MESH:D009771	abilify	aripiprazole	10MG	TABLET;ORAL	Prescription	AB	Yes	Yes
MESH:D009771	abilify	aripiprazole	1MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	SOLUTION;ORAL	Discontinued	None	Yes	No
MESH:D009771	abilify	aripiprazole	1MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	SOLUTION;ORAL	Discontinued	None	Yes	No
MESH:D009771	abilify	aripiprazole	10MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued	None	No	No
MESH:D009771	abilify	aripiprazole	10MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued	None	No	No
MESH:D009771	abilify	aripiprazole	9.75MG/1.3ML (7.5MG/ML)	INJECTABLE;INTRAMUSCULAR	Discontinued	None	No	No
MESH:D009771	abilify	aripiprazole	9.75MG/1.3ML (7.5MG/ML)	INJECTABLE;INTRAMUSCULAR	Discontinued	None	No	No
MESH:D009771	abilify	aripiprazole	10MG	TABLET;ORAL	Prescription	AB	Yes	Yes
MESH:D009771	abilify	aripiprazole	10MG	TABLET;ORAL	Prescription	AB	Yes	Yes
MESH:D009771	abilify	aripiprazole	1MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	SOLUTION;ORAL	Discontinued	None	Yes	No
MESH:D009771	abilify	aripiprazole	1MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	SOLUTION;ORAL	Discontinued	None	Yes	No
MESH:D009771	abilify	aripiprazole	10MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued	None	No	No
MESH:D009771	abilify	aripiprazole	10MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued	None	No	No
MESH:D009771	abilify	aripiprazole	9.75MG/1.3ML (7.5MG/ML)	INJECTABLE;INTRAMUSCULAR	Discontinued	None	No	No
MESH:D009771	abilify	aripiprazole	9.75MG/1.3ML (7.5MG/ML)	INJECTABLE;INTRAMUSCULAR	Discontinued	None	No	No
MESH:D009771	abilify	aripiprazole	10MG	TABLET;ORAL	Prescription	AB	Yes	Yes
MESH:D009771	abilify	aripiprazole	10MG	TABLET;ORAL	Prescription	AB	Yes	Yes
MESH:D009771	abilify	aripiprazole	1MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	SOLUTION;ORAL	Discontinued	None	Yes	No
MESH:D009771	abilify	aripiprazole	1MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	SOLUTION;ORAL	Discontinued	None	Yes	No
MESH:D009771	abilify	aripiprazole	10MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued	None	No	No
MESH:D009771	abilify	aripiprazole	10MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued	None	No	No
MESH:D009771	abilify	aripiprazole	9.75MG/1.3ML (7.5MG/ML)	INJECTABLE;INTRAMUSCULAR	Discontinued	None	No	No
MESH:D009771	abilify	aripiprazole	9.75MG/1.3ML (7.5MG/ML)	INJECTABLE;INTRAMUSCULAR	Discontinued	None	No	No
MESH:D009771	abilify	aripiprazole	10MG	TABLET;ORAL	Prescription	AB	Yes	Yes
MESH:D009771	abilify	aripiprazole	10MG	TABLET;ORAL	Prescription	AB	Yes	Yes
MESH:D009771	abilify	aripiprazole	1MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	SOLUTION;ORAL	Discontinued	None	Yes	No
MESH:D009771	abilify	aripiprazole	1MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	SOLUTION;ORAL	Discontinued	None	Yes	No
MESH:D009771	abilify	aripiprazole	10MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued	None	No	No
MESH:D009771	abilify	aripiprazole	10MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued	None	No	No
MESH:D009771	abilify	aripiprazole	9.75MG/1.3ML (7.5MG/ML)	INJECTABLE;INTRAMUSCULAR	Discontinued	None	No	No
MESH:D009771	abilify	aripiprazole	9.75MG/1.3ML (7.5MG/ML)	INJECTABLE;INTRAMUSCULAR	Discontinued	None	No	No
MESH:D009771	zyprexa	olanzapine	2.5MG	TABLET;ORAL	Prescription	AB	Yes	No
MESH:D009771	zyprexa	olanzapine	2.5MG	TABLET;ORAL	Prescription	AB	Yes	No
MESH:D009771	zyprexa	olanzapine	10MG/VIAL	INJECTABLE;INTRAMUSCULAR	Prescription	AP	Yes	Yes
MESH:D009771	zyprexa	olanzapine	10MG/VIAL	INJECTABLE;INTRAMUSCULAR	Prescription	AP	Yes	Yes
MESH:D009771	zyprexa	olanzapine	2.5MG	TABLET;ORAL	Prescription	AB	Yes	No
MESH:D009771	zyprexa	olanzapine	2.5MG	TABLET;ORAL	Prescription	AB	Yes	No
MESH:D009771	zyprexa	olanzapine	10MG/VIAL	INJECTABLE;INTRAMUSCULAR	Prescription	AP	Yes	Yes
MESH:D009771	zyprexa	olanzapine	10MG/VIAL	INJECTABLE;INTRAMUSCULAR	Prescription	AP	Yes	Yes
MESH:D009771	mirena	levonorgestrel	52MG	INTRAUTERINE DEVICE;INTRAUTERINE	Prescription	None	Yes	Yes
MESH:D009771	levonorgestrel	levonorgestrel	75MG/IMPLANT	IMPLANT;IMPLANTATION	Discontinued	None	No	No

FDA labeling changes(Total Drugs:46)
DiseaseID	Pediatric_Labeling_Date	Trade_Name	Generic_Name_or_Proper_Name	Indications Studied	Label Changes Summary	Product Labeling	BPCA(B)	PREA(P)	BPCA(B) and PREA(P)	Pediatric Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	NNPS
MESH:D009771	12/1/2005	remeron	mirtazapine	Major Depressive Disorder	Safety and effectiveness in the pediatric population have not been established FDA required boxed warning for all antidepressants: Suicidality in Children and Adolescents - Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children and adolescents with Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of Remeron or any other antidepressant in a child or adolescent must balance this risk with the clinical need. Patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Remeron is not approved for use in pediatric patients. (See Warnings and Precautions: Pediatric Use) Pooled analyses of short-term (4 to 16 weeks) placebo-controlled trials of 9 antidepressant drugs (SSRIs and others) in children and adolescents with major depressive disorder (MDD), obsessive compulsive disorder (OCD), or other psychiatric disorders (a total of 24 trials involving over 4400 patients) have revealed a greater risk of adverse events representing suicidal thinking or behavior (suicidality) during the first few months of treatment in those receiving antidepressants. The average risk of such events in patients receiving antidepressants was 4%, twice the placebo risk of 2%. No suicides occurred in these trials Two placebo-controlled trials in 258 pediatric patients with MDD have been conducted with Remeron and the data were not sufficient to support a claim for use in pediatric patients	Labeling	B	-	-	-	Organon	-	FALSE'
MESH:D009771	6/4/2006	daytrana	methylphenidate	ADHD	Summary is pending	Labeling	-	P	-	-	Shire	-	FALSE'
MESH:D009771	12/14/2009	daytrana	methylphenidate	Postmarketing safety study	Information added to Warnings and Adverse Reactions on skin reactions observed in a postmarketing dermal study in pediatric patients	Labeling	-	P	-	-	Shire	-	FALSE'
MESH:D009771	06/29/2010	daytrana	methylphenidate	ADHD	Expanded pediatric indication to include adolescent patients ages13-17 years The most commonly reported adverse reactions in a trial in patients 13-17 years included appetite decreased, nausea, insomnia, weight decreased, dizziness, abdominal pain, and anorexia. The majority of patients had erythema at the application site Information on PK parameters, Adverse Event profile and clinical studies	Labeling	-	P	-	-	Shire	-	FALSE'
MESH:D009771	10/29/2007	abilify	aripiprazole	Schizophrenia	Extended schizophrenia indication from adults to adolescents 1317 years Safety and effectiveness in pediatric patients with bipolar mania or agitation associated with schizophrenia or bipolar mania have not been established Efficacy for the maintenance treatment of schizophrenia in the pediatric population has not been evaluated In 6-week placebo controlled efficacy trial in patients 13 17 years with Schizophrenia 30 mg/day was not shown to be more efficacious than 10 mg/day Common adverse events observed were extrapyramidal disorder, somnolence, and tremor; these 3 AEs appear to have a possible dose response relationship Information on dose, AEs, clinical studies	Labeling	B	-	-	-	Otsuka	11/14/2007	FALSE'
MESH:D009771	10/29/2007	abilify	aripiprazole	Schizophrenia	Extended schizophrenia indication from adults to adolescents 1317 years Safety and effectiveness in pediatric patients with bipolar mania or agitation associated with schizophrenia or bipolar mania have not been established Efficacy for the maintenance treatment of schizophrenia in the pediatric population has not been evaluated In 6-week placebo controlled efficacy trial in patients 13 17 years with Schizophrenia 30 mg/day was not shown to be more efficacious than 10 mg/day Common adverse events observed were extrapyramidal disorder, somnolence, and tremor; these 3 AEs appear to have a possible dose response relationship Information on dose, AEs, clinical studies	Labeling	B	-	-	-	Otsuka	11/14/2007	FALSE'
MESH:D009771	10/29/2007	abilify	aripiprazole	Schizophrenia	Extended schizophrenia indication from adults to adolescents 1317 years Safety and effectiveness in pediatric patients with bipolar mania or agitation associated with schizophrenia or bipolar mania have not been established Efficacy for the maintenance treatment of schizophrenia in the pediatric population has not been evaluated In 6-week placebo controlled efficacy trial in patients 13 17 years with Schizophrenia 30 mg/day was not shown to be more efficacious than 10 mg/day Common adverse events observed were extrapyramidal disorder, somnolence, and tremor; these 3 AEs appear to have a possible dose response relationship Information on dose, AEs, clinical studies	Labeling	B	-	-	-	Otsuka	11/14/2007	FALSE'
MESH:D009771	10/29/2007	abilify	aripiprazole	Schizophrenia	Extended schizophrenia indication from adults to adolescents 1317 years Safety and effectiveness in pediatric patients with bipolar mania or agitation associated with schizophrenia or bipolar mania have not been established Efficacy for the maintenance treatment of schizophrenia in the pediatric population has not been evaluated In 6-week placebo controlled efficacy trial in patients 13 17 years with Schizophrenia 30 mg/day was not shown to be more efficacious than 10 mg/day Common adverse events observed were extrapyramidal disorder, somnolence, and tremor; these 3 AEs appear to have a possible dose response relationship Information on dose, AEs, clinical studies	Labeling	B	-	-	-	Otsuka	11/14/2007	FALSE'
MESH:D009771	10/29/2007	abilify	aripiprazole	Schizophrenia	Extended schizophrenia indication from adults to adolescents 1317 years Safety and effectiveness in pediatric patients with bipolar mania or agitation associated with schizophrenia or bipolar mania have not been established Efficacy for the maintenance treatment of schizophrenia in the pediatric population has not been evaluated In 6-week placebo controlled efficacy trial in patients 13 17 years with Schizophrenia 30 mg/day was not shown to be more efficacious than 10 mg/day Common adverse events observed were extrapyramidal disorder, somnolence, and tremor; these 3 AEs appear to have a possible dose response relationship Information on dose, AEs, clinical studies	Labeling	B	-	-	-	Otsuka	11/14/2007	FALSE'
MESH:D009771	10/29/2007	abilify	aripiprazole	Schizophrenia	Extended schizophrenia indication from adults to adolescents 1317 years Safety and effectiveness in pediatric patients with bipolar mania or agitation associated with schizophrenia or bipolar mania have not been established Efficacy for the maintenance treatment of schizophrenia in the pediatric population has not been evaluated In 6-week placebo controlled efficacy trial in patients 13 17 years with Schizophrenia 30 mg/day was not shown to be more efficacious than 10 mg/day Common adverse events observed were extrapyramidal disorder, somnolence, and tremor; these 3 AEs appear to have a possible dose response relationship Information on dose, AEs, clinical studies	Labeling	B	-	-	-	Otsuka	11/14/2007	FALSE'
MESH:D009771	10/29/2007	abilify	aripiprazole	Schizophrenia	Extended schizophrenia indication from adults to adolescents 1317 years Safety and effectiveness in pediatric patients with bipolar mania or agitation associated with schizophrenia or bipolar mania have not been established Efficacy for the maintenance treatment of schizophrenia in the pediatric population has not been evaluated In 6-week placebo controlled efficacy trial in patients 13 17 years with Schizophrenia 30 mg/day was not shown to be more efficacious than 10 mg/day Common adverse events observed were extrapyramidal disorder, somnolence, and tremor; these 3 AEs appear to have a possible dose response relationship Information on dose, AEs, clinical studies	Labeling	B	-	-	-	Otsuka	11/14/2007	FALSE'
MESH:D009771	10/29/2007	abilify	aripiprazole	Schizophrenia	Extended schizophrenia indication from adults to adolescents 1317 years Safety and effectiveness in pediatric patients with bipolar mania or agitation associated with schizophrenia or bipolar mania have not been established Efficacy for the maintenance treatment of schizophrenia in the pediatric population has not been evaluated In 6-week placebo controlled efficacy trial in patients 13 17 years with Schizophrenia 30 mg/day was not shown to be more efficacious than 10 mg/day Common adverse events observed were extrapyramidal disorder, somnolence, and tremor; these 3 AEs appear to have a possible dose response relationship Information on dose, AEs, clinical studies	Labeling	B	-	-	-	Otsuka	11/14/2007	FALSE'
MESH:D009771	02/27/2008	abilify	aripiprazole	Bipolar I Disorder	Extended treatment of acute Bipolar Disorder indication from adults to pediatrics 1017 years The efficacy for the maintenance treatment of Bipolar Disorder in the pediatric population has not been evaluated The recommended target dose in Bipolar Disorder is 10 mg/day. In the study of pediatric patients 10 17 years with Bipolar Mania, 4 common adverse reactions had a possible dose response relationship at 4 weeks; extrapyramidal disorder, somnolence, akathisia and salivary hypersecretion Information on dose, AEs, clinical studies	Labeling	-	-	B, P	-	Otsuka	11/14/2007	FALSE'
MESH:D009771	02/27/2008	abilify	aripiprazole	Bipolar I Disorder	Extended treatment of acute Bipolar Disorder indication from adults to pediatrics 1017 years The efficacy for the maintenance treatment of Bipolar Disorder in the pediatric population has not been evaluated The recommended target dose in Bipolar Disorder is 10 mg/day. In the study of pediatric patients 10 17 years with Bipolar Mania, 4 common adverse reactions had a possible dose response relationship at 4 weeks; extrapyramidal disorder, somnolence, akathisia and salivary hypersecretion Information on dose, AEs, clinical studies	Labeling	-	-	B, P	-	Otsuka	11/14/2007	FALSE'
MESH:D009771	02/27/2008	abilify	aripiprazole	Bipolar I Disorder	Extended treatment of acute Bipolar Disorder indication from adults to pediatrics 1017 years The efficacy for the maintenance treatment of Bipolar Disorder in the pediatric population has not been evaluated The recommended target dose in Bipolar Disorder is 10 mg/day. In the study of pediatric patients 10 17 years with Bipolar Mania, 4 common adverse reactions had a possible dose response relationship at 4 weeks; extrapyramidal disorder, somnolence, akathisia and salivary hypersecretion Information on dose, AEs, clinical studies	Labeling	-	-	B, P	-	Otsuka	11/14/2007	FALSE'
MESH:D009771	02/27/2008	abilify	aripiprazole	Bipolar I Disorder	Extended treatment of acute Bipolar Disorder indication from adults to pediatrics 1017 years The efficacy for the maintenance treatment of Bipolar Disorder in the pediatric population has not been evaluated The recommended target dose in Bipolar Disorder is 10 mg/day. In the study of pediatric patients 10 17 years with Bipolar Mania, 4 common adverse reactions had a possible dose response relationship at 4 weeks; extrapyramidal disorder, somnolence, akathisia and salivary hypersecretion Information on dose, AEs, clinical studies	Labeling	-	-	B, P	-	Otsuka	11/14/2007	FALSE'
MESH:D009771	02/27/2008	abilify	aripiprazole	Bipolar I Disorder	Extended treatment of acute Bipolar Disorder indication from adults to pediatrics 1017 years The efficacy for the maintenance treatment of Bipolar Disorder in the pediatric population has not been evaluated The recommended target dose in Bipolar Disorder is 10 mg/day. In the study of pediatric patients 10 17 years with Bipolar Mania, 4 common adverse reactions had a possible dose response relationship at 4 weeks; extrapyramidal disorder, somnolence, akathisia and salivary hypersecretion Information on dose, AEs, clinical studies	Labeling	-	-	B, P	-	Otsuka	11/14/2007	FALSE'
MESH:D009771	02/27/2008	abilify	aripiprazole	Bipolar I Disorder	Extended treatment of acute Bipolar Disorder indication from adults to pediatrics 1017 years The efficacy for the maintenance treatment of Bipolar Disorder in the pediatric population has not been evaluated The recommended target dose in Bipolar Disorder is 10 mg/day. In the study of pediatric patients 10 17 years with Bipolar Mania, 4 common adverse reactions had a possible dose response relationship at 4 weeks; extrapyramidal disorder, somnolence, akathisia and salivary hypersecretion Information on dose, AEs, clinical studies	Labeling	-	-	B, P	-	Otsuka	11/14/2007	FALSE'
MESH:D009771	02/27/2008	abilify	aripiprazole	Bipolar I Disorder	Extended treatment of acute Bipolar Disorder indication from adults to pediatrics 1017 years The efficacy for the maintenance treatment of Bipolar Disorder in the pediatric population has not been evaluated The recommended target dose in Bipolar Disorder is 10 mg/day. In the study of pediatric patients 10 17 years with Bipolar Mania, 4 common adverse reactions had a possible dose response relationship at 4 weeks; extrapyramidal disorder, somnolence, akathisia and salivary hypersecretion Information on dose, AEs, clinical studies	Labeling	-	-	B, P	-	Otsuka	11/14/2007	FALSE'
MESH:D009771	02/27/2008	abilify	aripiprazole	Bipolar I Disorder	Extended treatment of acute Bipolar Disorder indication from adults to pediatrics 1017 years The efficacy for the maintenance treatment of Bipolar Disorder in the pediatric population has not been evaluated The recommended target dose in Bipolar Disorder is 10 mg/day. In the study of pediatric patients 10 17 years with Bipolar Mania, 4 common adverse reactions had a possible dose response relationship at 4 weeks; extrapyramidal disorder, somnolence, akathisia and salivary hypersecretion Information on dose, AEs, clinical studies	Labeling	-	-	B, P	-	Otsuka	11/14/2007	FALSE'
MESH:D009771	11/19/2009	abilify	aripiprazole	Irritability associated with autistic disorder	Safety and effectiveness in pediatric patients demonstrating irritability associated with autistic disorder were established in two placebo-controlled clinical trials in pediatric patients 6 - 17 years of age Most common adverse reactions observed in pediatric clinical trials in patients with autistic disorder included sedation, fatigue, vomiting, somnolence, tremor, pyrexia, drooling, decreased appetite, salivary hypersecretion, extrapyramidal disorder, and lethargy. Fatigue was a possible dose-response adverse reaction. Information on dosing, adverse reactions, and clinical studies	Labeling	-	P	-	-	Otsuka	-	FALSE'
MESH:D009771	11/19/2009	abilify	aripiprazole	Irritability associated with autistic disorder	Safety and effectiveness in pediatric patients demonstrating irritability associated with autistic disorder were established in two placebo-controlled clinical trials in pediatric patients 6 - 17 years of age Most common adverse reactions observed in pediatric clinical trials in patients with autistic disorder included sedation, fatigue, vomiting, somnolence, tremor, pyrexia, drooling, decreased appetite, salivary hypersecretion, extrapyramidal disorder, and lethargy. Fatigue was a possible dose-response adverse reaction. Information on dosing, adverse reactions, and clinical studies	Labeling	-	P	-	-	Otsuka	-	FALSE'
MESH:D009771	11/19/2009	abilify	aripiprazole	Irritability associated with autistic disorder	Safety and effectiveness in pediatric patients demonstrating irritability associated with autistic disorder were established in two placebo-controlled clinical trials in pediatric patients 6 - 17 years of age Most common adverse reactions observed in pediatric clinical trials in patients with autistic disorder included sedation, fatigue, vomiting, somnolence, tremor, pyrexia, drooling, decreased appetite, salivary hypersecretion, extrapyramidal disorder, and lethargy. Fatigue was a possible dose-response adverse reaction. Information on dosing, adverse reactions, and clinical studies	Labeling	-	P	-	-	Otsuka	-	FALSE'
MESH:D009771	11/19/2009	abilify	aripiprazole	Irritability associated with autistic disorder	Safety and effectiveness in pediatric patients demonstrating irritability associated with autistic disorder were established in two placebo-controlled clinical trials in pediatric patients 6 - 17 years of age Most common adverse reactions observed in pediatric clinical trials in patients with autistic disorder included sedation, fatigue, vomiting, somnolence, tremor, pyrexia, drooling, decreased appetite, salivary hypersecretion, extrapyramidal disorder, and lethargy. Fatigue was a possible dose-response adverse reaction. Information on dosing, adverse reactions, and clinical studies	Labeling	-	P	-	-	Otsuka	-	FALSE'
MESH:D009771	11/19/2009	abilify	aripiprazole	Irritability associated with autistic disorder	Safety and effectiveness in pediatric patients demonstrating irritability associated with autistic disorder were established in two placebo-controlled clinical trials in pediatric patients 6 - 17 years of age Most common adverse reactions observed in pediatric clinical trials in patients with autistic disorder included sedation, fatigue, vomiting, somnolence, tremor, pyrexia, drooling, decreased appetite, salivary hypersecretion, extrapyramidal disorder, and lethargy. Fatigue was a possible dose-response adverse reaction. Information on dosing, adverse reactions, and clinical studies	Labeling	-	P	-	-	Otsuka	-	FALSE'
MESH:D009771	11/19/2009	abilify	aripiprazole	Irritability associated with autistic disorder	Safety and effectiveness in pediatric patients demonstrating irritability associated with autistic disorder were established in two placebo-controlled clinical trials in pediatric patients 6 - 17 years of age Most common adverse reactions observed in pediatric clinical trials in patients with autistic disorder included sedation, fatigue, vomiting, somnolence, tremor, pyrexia, drooling, decreased appetite, salivary hypersecretion, extrapyramidal disorder, and lethargy. Fatigue was a possible dose-response adverse reaction. Information on dosing, adverse reactions, and clinical studies	Labeling	-	P	-	-	Otsuka	-	FALSE'
MESH:D009771	11/19/2009	abilify	aripiprazole	Irritability associated with autistic disorder	Safety and effectiveness in pediatric patients demonstrating irritability associated with autistic disorder were established in two placebo-controlled clinical trials in pediatric patients 6 - 17 years of age Most common adverse reactions observed in pediatric clinical trials in patients with autistic disorder included sedation, fatigue, vomiting, somnolence, tremor, pyrexia, drooling, decreased appetite, salivary hypersecretion, extrapyramidal disorder, and lethargy. Fatigue was a possible dose-response adverse reaction. Information on dosing, adverse reactions, and clinical studies	Labeling	-	P	-	-	Otsuka	-	FALSE'
MESH:D009771	11/19/2009	abilify	aripiprazole	Irritability associated with autistic disorder	Safety and effectiveness in pediatric patients demonstrating irritability associated with autistic disorder were established in two placebo-controlled clinical trials in pediatric patients 6 - 17 years of age Most common adverse reactions observed in pediatric clinical trials in patients with autistic disorder included sedation, fatigue, vomiting, somnolence, tremor, pyrexia, drooling, decreased appetite, salivary hypersecretion, extrapyramidal disorder, and lethargy. Fatigue was a possible dose-response adverse reaction. Information on dosing, adverse reactions, and clinical studies	Labeling	-	P	-	-	Otsuka	-	FALSE'
MESH:D009771	9/6/2014	abilify	aripiprazole	Maintenance treatment of irritability associated with autistic disorder	Efficacy for the maintenance treatment of irritability associated with autistic disorder was not established in a 12 week clinical trial in 85 pediatric patients 6-17 years Information on clinical trialPostmarketing study	Labeling	-	P	-	-	Otsuka	-	FALSE'
MESH:D009771	9/6/2014	abilify	aripiprazole	Maintenance treatment of irritability associated with autistic disorder	Efficacy for the maintenance treatment of irritability associated with autistic disorder was not established in a 12 week clinical trial in 85 pediatric patients 6-17 years Information on clinical trialPostmarketing study	Labeling	-	P	-	-	Otsuka	-	FALSE'
MESH:D009771	9/6/2014	abilify	aripiprazole	Maintenance treatment of irritability associated with autistic disorder	Efficacy for the maintenance treatment of irritability associated with autistic disorder was not established in a 12 week clinical trial in 85 pediatric patients 6-17 years Information on clinical trialPostmarketing study	Labeling	-	P	-	-	Otsuka	-	FALSE'
MESH:D009771	9/6/2014	abilify	aripiprazole	Maintenance treatment of irritability associated with autistic disorder	Efficacy for the maintenance treatment of irritability associated with autistic disorder was not established in a 12 week clinical trial in 85 pediatric patients 6-17 years Information on clinical trialPostmarketing study	Labeling	-	P	-	-	Otsuka	-	FALSE'
MESH:D009771	9/6/2014	abilify	aripiprazole	Maintenance treatment of irritability associated with autistic disorder	Efficacy for the maintenance treatment of irritability associated with autistic disorder was not established in a 12 week clinical trial in 85 pediatric patients 6-17 years Information on clinical trialPostmarketing study	Labeling	-	P	-	-	Otsuka	-	FALSE'
MESH:D009771	9/6/2014	abilify	aripiprazole	Maintenance treatment of irritability associated with autistic disorder	Efficacy for the maintenance treatment of irritability associated with autistic disorder was not established in a 12 week clinical trial in 85 pediatric patients 6-17 years Information on clinical trialPostmarketing study	Labeling	-	P	-	-	Otsuka	-	FALSE'
MESH:D009771	9/6/2014	abilify	aripiprazole	Maintenance treatment of irritability associated with autistic disorder	Efficacy for the maintenance treatment of irritability associated with autistic disorder was not established in a 12 week clinical trial in 85 pediatric patients 6-17 years Information on clinical trialPostmarketing study	Labeling	-	P	-	-	Otsuka	-	FALSE'
MESH:D009771	9/6/2014	abilify	aripiprazole	Maintenance treatment of irritability associated with autistic disorder	Efficacy for the maintenance treatment of irritability associated with autistic disorder was not established in a 12 week clinical trial in 85 pediatric patients 6-17 years Information on clinical trialPostmarketing study	Labeling	-	P	-	-	Otsuka	-	FALSE'
MESH:D009771	08/14/2008	zyprexa	olanzapine	schizophrenia; bipolar disorder	Safety and effectiveness have not been established for patients less than 18 years of age In an analysis of placebo-controlled olanzapine monotherapy studies of adolescent patients, including those with schizophrenia or bipolar disorder, olanzapine was associated with: oHyperglycemia - a statistically significantly greater mean change in fasting glucose levels compared to placebo oHyperlipidemia statistically significant increases compared to placebo in fasting triglycerides, fasting total cholesterol and fasting LDL cholesterol oWeight gain olanzapine treated patients gained an average of 4.6 kg, compared to an average of 0.3 kg in placebo-treated patients with a median exposure of 3 weeks; Average weight gain during long-term therapy was 7.4 kg	-	B	-	-	-	Lilly	10/1/2007	FALSE'
MESH:D009771	08/14/2008	zyprexa	olanzapine	schizophrenia; bipolar disorder	Safety and effectiveness have not been established for patients less than 18 years of age In an analysis of placebo-controlled olanzapine monotherapy studies of adolescent patients, including those with schizophrenia or bipolar disorder, olanzapine was associated with: oHyperglycemia - a statistically significantly greater mean change in fasting glucose levels compared to placebo oHyperlipidemia statistically significant increases compared to placebo in fasting triglycerides, fasting total cholesterol and fasting LDL cholesterol oWeight gain olanzapine treated patients gained an average of 4.6 kg, compared to an average of 0.3 kg in placebo-treated patients with a median exposure of 3 weeks; Average weight gain during long-term therapy was 7.4 kg	-	B	-	-	-	Lilly	10/1/2007	FALSE'
MESH:D009771	08/14/2008	zyprexa	olanzapine	schizophrenia; bipolar disorder	Safety and effectiveness have not been established for patients less than 18 years of age In an analysis of placebo-controlled olanzapine monotherapy studies of adolescent patients, including those with schizophrenia or bipolar disorder, olanzapine was associated with: oHyperglycemia - a statistically significantly greater mean change in fasting glucose levels compared to placebo oHyperlipidemia statistically significant increases compared to placebo in fasting triglycerides, fasting total cholesterol and fasting LDL cholesterol oWeight gain olanzapine treated patients gained an average of 4.6 kg, compared to an average of 0.3 kg in placebo-treated patients with a median exposure of 3 weeks; Average weight gain during long-term therapy was 7.4 kg	-	B	-	-	-	Lilly	10/1/2007	FALSE'
MESH:D009771	08/14/2008	zyprexa	olanzapine	schizophrenia; bipolar disorder	Safety and effectiveness have not been established for patients less than 18 years of age In an analysis of placebo-controlled olanzapine monotherapy studies of adolescent patients, including those with schizophrenia or bipolar disorder, olanzapine was associated with: oHyperglycemia - a statistically significantly greater mean change in fasting glucose levels compared to placebo oHyperlipidemia statistically significant increases compared to placebo in fasting triglycerides, fasting total cholesterol and fasting LDL cholesterol oWeight gain olanzapine treated patients gained an average of 4.6 kg, compared to an average of 0.3 kg in placebo-treated patients with a median exposure of 3 weeks; Average weight gain during long-term therapy was 7.4 kg	-	B	-	-	-	Lilly	10/1/2007	FALSE'
MESH:D009771	4/12/2009	zyprexa	olanzapine	Treatment of manic or mixed episodes of bipolar I disorder and schizophrenia in adolescents ages 13-17	Extended schizophrenia and manic or mixed episodes of bipolar I disorder indications from adults to adolescents 1317 years of age Safety and effectiveness in children < 13 years of age have not been established Recommended starting dose for adolescents is lower than that for adults Compared to patients from adult clinical trials, adolescents were likely to gain more weight, experience increased sedation, and have greater increases in total cholesterol, triglycerides, LDL cholesterol, prolactin and hepatic transaminase levels Information on dosing, adverse reactions, pharmacokinetics, clinical studies	Labeling	B	-	-	-	Lilly	10/1/2007	TRUE'
MESH:D009771	4/12/2009	zyprexa	olanzapine	Treatment of manic or mixed episodes of bipolar I disorder and schizophrenia in adolescents ages 13-17	Extended schizophrenia and manic or mixed episodes of bipolar I disorder indications from adults to adolescents 1317 years of age Safety and effectiveness in children < 13 years of age have not been established Recommended starting dose for adolescents is lower than that for adults Compared to patients from adult clinical trials, adolescents were likely to gain more weight, experience increased sedation, and have greater increases in total cholesterol, triglycerides, LDL cholesterol, prolactin and hepatic transaminase levels Information on dosing, adverse reactions, pharmacokinetics, clinical studies	Labeling	B	-	-	-	Lilly	10/1/2007	TRUE'
MESH:D009771	4/12/2009	zyprexa	olanzapine	Treatment of manic or mixed episodes of bipolar I disorder and schizophrenia in adolescents ages 13-17	Extended schizophrenia and manic or mixed episodes of bipolar I disorder indications from adults to adolescents 1317 years of age Safety and effectiveness in children < 13 years of age have not been established Recommended starting dose for adolescents is lower than that for adults Compared to patients from adult clinical trials, adolescents were likely to gain more weight, experience increased sedation, and have greater increases in total cholesterol, triglycerides, LDL cholesterol, prolactin and hepatic transaminase levels Information on dosing, adverse reactions, pharmacokinetics, clinical studies	Labeling	B	-	-	-	Lilly	10/1/2007	TRUE'
MESH:D009771	4/12/2009	zyprexa	olanzapine	Treatment of manic or mixed episodes of bipolar I disorder and schizophrenia in adolescents ages 13-17	Extended schizophrenia and manic or mixed episodes of bipolar I disorder indications from adults to adolescents 1317 years of age Safety and effectiveness in children < 13 years of age have not been established Recommended starting dose for adolescents is lower than that for adults Compared to patients from adult clinical trials, adolescents were likely to gain more weight, experience increased sedation, and have greater increases in total cholesterol, triglycerides, LDL cholesterol, prolactin and hepatic transaminase levels Information on dosing, adverse reactions, pharmacokinetics, clinical studies	Labeling	B	-	-	-	Lilly	10/1/2007	TRUE'
MESH:D009771	1/10/2009	mirena	levonorgestrel-releasing intrauterine system	Treatment of heavy menstrual bleeding for women using intrauterine contraception	New indication for the treatment of heavy menstrual bleeding for women who choose to use intrauterine contraception Use before menarche is not indicated	Labeling	-	P	-	-	Berlex	-	TRUE'
MESH:D009771	10/7/2009	plan b one step	levonorgestrel	Emergency contraception - OTC in women 17 years and older; RX for women younger than age 17 years	New single dose 1.5 mg tablet New dosage regimen	Labeling	-	P	-	-	Duramed	-	FALSE'